An epidemiOlogy Study to deteRmine the Prevalence of EGFR (Epidermal Growth Factor Receptor) muTations in RUSsian Patients With Advanced NSCLC (Non-Small Cell Lung Cancer).
NCT ID: NCT02321046
Last Updated: 2020-06-29
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
26 participants
OBSERVATIONAL
2015-09-02
2019-06-28
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Non-interventional, Prospective Study to Determine Prevalence of EGFR Mutations in Non-small Cell Lung Cancer
NCT04742192
Asia Pacific and Russia Diagnostic Study for EGFR Testing
NCT01788163
Epidemiological Study to Evaluate the Prevalence of Epidermal Growth Factor Receptor (EGFR) Mutation Status in Patients With Newly Diagnosed Locally Advanced or Metastatic Non Small Cell Lung Cancer (NSCLC)
NCT01081496
Study to Evaluate Concordance of Detecting EGFR (Epidermal Growth Factor Receptor) Mutation by Circulating Tumour Free DNA Versus Tissues Biopsy in NSCLC (Non-small Cell Lung Cancer).
NCT03562819
A Molecular Profiling Study of Patients With EGFR Mutation-positive Locally Advanced or Metastatic NSCLC Treated With Osimertinib
NCT03239340
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
It is planned to enrol approximately 300 subjects in Russian Federation. Approximately 60 EGFR m+ (mutation-positive) patients will be followed for 1.5 years.
EGFR mutations rate before treatment in cytology and plasma samples in treatment-naive patients with advanced NSCLC in Russia is considered as the primary outcome variable in this study.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_ONLY
PROSPECTIVE
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Quality and quantity of the cytological sample material meeting the requirements of the molecular-genetic testing
* No previous/ ongoing treatment for NSCLC at the moment of recruitment
Exclusion Criteria
* Any medical condition which on the opinion of the investigator may interfere the patient's participation in the study
* Quality and quantity of the cytological sample material insufficient for the molecular-genetic testing
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
AstraZeneca
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Alexander Bedenkov, MCMD
Role: STUDY_DIRECTOR
AstraZeneca
Konstantin Lactionov, Professor
Role: PRINCIPAL_INVESTIGATOR
Russian Cancer Research Center named after N.N.Blokhin
Irina Demidova, PHD
Role: PRINCIPAL_INVESTIGATOR
Moscow City Clinical Cancer Hospital #62
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Research Site
Khanti-Manskiysk, Russia, Russia
Research Site
Novisibirsk, Russia, Russia
Research Site
Arkhangelsk, , Russia
Research Site
Barnaul, , Russia
Research Site
Chelyabinsk, , Russia
Research Site
Irkutsk, , Russia
Research Site
Kemerovo, , Russia
Research Site
Khabarovsk, , Russia
Research Site
Kirov, , Russia
Research Site
Krasnodar, , Russia
Research Site
Krasnoyarsk, , Russia
Research Site
Moscow, , Russia
Research Site
Nizhny Novgorod, , Russia
Research Site
Novosibirsk, , Russia
Research Site
Obninsk, , Russia
Research Site
Omsk, , Russia
Research Site
Orenburg, , Russia
Research Site
Rostov-on-Don, , Russia
Research Site
Saint Petersburg, , Russia
Research Site
Samara, , Russia
Research Site
Tambov, , Russia
Research Site
Tomsk, , Russia
Research Site
Ufa, , Russia
Research Site
Vladivostok, , Russia
Research Site
Volgograd, , Russia
Research Site
Yuzhno-Sakhalinsk, , Russia
Countries
Review the countries where the study has at least one active or historical site.
Related Links
Access external resources that provide additional context or updates about the study.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
D133FR00101
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.